Department of Oncology and Palliative Medicine, Nordland Hospital, Bodo, Norway.
Clin Transl Oncol. 2011 Dec;13(12):885-8. doi: 10.1007/s12094-011-0750-6.
PURPOSE To evaluate whether reduced overall treatment time (OTT), i.e., administration of more than 5 fractions per week, or uncompensated treatment interruption resulting in increased OTT influences survival of patients treated with whole-brain radiotherapy (WBRT) for brain metastases. METHODS Retrospective multi-institutional intention-to-treat study including 233 patients treated with primary WBRT (prescribed dose 10 fractions of 3 Gy; no previous SRS or surgery) administered over 10-38 days. Four groups were studied: OTT 10-11 vs. 12 days, 13-15 or >15 days. RESULTS Fourteen patients (6%) failed to complete WBRT and received 3-9 fractions (median 7). Their median survival was 0.5 months as compared to 3 months in patients who completed WBRT. No significant impact of OTT on survival was found. Median survival was 1.5, 2.9, 3.0 and 3.1 months in the four groups mentioned above. CONCLUSIONS Compensation for unintended treatment interruption is generally recommended but might not always be feasible. Depending on histological tumour type or expected repopulation, prognostic factors and neurological status, it might be acceptable to complete an interrupted course of WBRT without compensation in selected patients. While survival might be largely independent from OTT, it should also be evaluated whether this parameter has any impact on quality of life and duration of palliation.
评估每周接受超过 5 次治疗的总治疗时间(OTT)减少或未补偿的治疗中断导致 OTT 增加是否会影响脑转移患者接受全脑放疗(WBRT)的生存。
这是一项回顾性多机构意向治疗研究,共纳入 233 例接受原发 WBRT(规定剂量为 10 个 3Gy 剂量;无先前 SRS 或手术)治疗的患者,治疗时间为 10-38 天。研究了四个组:OTT 为 10-11 天与 12 天、13-15 天或 >15 天。
14 例患者(6%)未能完成 WBRT,仅接受了 3-9 次治疗(中位数为 7 次)。他们的中位生存期为 0.5 个月,而完成 WBRT 的患者中位生存期为 3 个月。OTT 对生存无显著影响。上述四个组的中位生存期分别为 1.5、2.9、3.0 和 3.1 个月。
通常建议对非故意的治疗中断进行补偿,但补偿可能并不总是可行的。根据组织学肿瘤类型或预期的再增殖、预后因素和神经状态,在选定的患者中,无需补偿即可完成中断的 WBRT 治疗可能是可以接受的。虽然生存可能在很大程度上独立于 OTT,但也应该评估该参数是否会对生活质量和缓解持续时间产生影响。